Gender Impact On Health Is Huge - Women's Health Research Needs More Investments
43m
·
Faces of Digital Health
·
Migraine is 3 times more common in women than in men. 2/3 of patients with Alzheimer’s disease. Gender differences are real and they matter. The Women's Brain Project (WBP) is a Swiss-based international non-profit organization founded in 2016. It comprises a diverse team of academic and social scientists, medical doctors, engineers, patients, caregivers, artists, and AI experts. The WBP focuses on understanding sex and gender differences in brain and mental diseases to pave the way for precision medicine. This involves tailoring medical treatment to the individual characteristics of each patient, including factors like sex, gender, genomic and proteomics, microbiome, ethnicity, and socio-economic status. In this episodeAntonella Santuccione Chadha, medical doctor and CEO of Women’s brain project and Anna De, Head of Stakeholder Engagement at Women's Brain Project explain: where are we with data about women’s health specifics, what is driving research in women’s health, what is the negative health and societal impact on women because of their predominant role in caregiving. Show notes: [00:03:01] Antonella Discusses Women's Brain Project: The gaps in medicine for not considering sex and gender. The transformation from an association to a foundation. The need for commitment and support for evidence generation. [00:05:20] Underrepresentation of Women in Research: Antonella explains historical exclusion of women and the current need for inclusion. Addressing biases and the importance of female leadership in medicine. [00:08:23] Evaluating Existing and New Treatments: The role of real-world data in addressing the gap in gender responses to treatments. [00:11:27] Key Findings and Successes: Antonella passes the conversation to Anna to discuss policy successes. [00:11:59] Anna Discusses Policy Impact: How Women's Brain Project informs global policy. Collaboration with large organizations and efforts to influence policy. [00:16:01] Migraine Research and Campaigns: Details on the migraine awareness campaign and insights on how it impacts women specifically. [00:19:30] Antonella on Scientific Evidence: The role of female hormones in migraines and other diseases. The importance of translating science into political measures. [00:20:38] Alzheimer's Disease in Women: Discussion on why two-thirds of Alzheimer's patients are women and associated factors. [00:26:00] Relationship Between Research and Medical Practice: Antonella shares her experiences as a clinician and the realization of gender disparities in her patients. The importance of educating healthcare professionals on sex and gender differences. [00:29:03] Anna Adds to the Discussion: The need to consider both sex and gender differences in healthcare. The societal impact of caregiver burden on women. [00:33:34] Identifying Questions and Approaches for Research: The conversation turns to the complexities of starting research with the right questions and data. [00:37:18] Key Changes Needed to Advance Women's Health: Antonella and Anna discuss the three key changes they hope to see: investment in women-driven innovation, prioritizing sex and gender differences in policy agendas, and empowering women with knowledge about their health. [00:41:34] Closing Remarks: The need for more research and better patient management, especially regarding menopause. The call for the younger female generation to lead change. Newsletter: https://fodh.substack.com/ www.facesofdigitalhealth.com
The episode Gender Impact On Health Is Huge - Women's Health Research Needs More Investments from the podcast Faces of Digital Health has a duration of
43:31. It was first published
More episodes from Faces of Digital Health
Learning From pan-Canadian Health Data Strategy - What's Next to EHDS? (Eric Sutherland)
The European Health Data Space is around the corner. The legislation is confirmed. How do we get to the next steps? Today you will hear a discussion with Eric Sutherland, Senior Health Economist and Digital Health Lead at OECD, who worked on the pan-Canadian health data strategy before his current role.We discussed the upcoming implementation of the European Health Data Space, what needs to happen next, how do we involve the public, encourage trust in data sharing, and also build capacity for digital health implementation. We are moving into the era of new required data professionals, not just data analysts, but also data controllers, data stewards and more. www.facesofdigitalhealth.com Newsletter: https://fodh.substack.com/ Show notes: [00:02:00] - Eric Sutherland's background and transition from Canada to OECD [00:04:00] - Challenges and solutions in Canadian health data strategy, emphasizing the need for data stewardship and public engagement [00:06:00] - Importance of data interoperability and policy compatibility across regions [00:08:00] - Goals of Canadian health data strategy and its impact, focusing on improving healthcare delivery through better data utilization. [00:10:00] - Governance and collective impact in Canadian healthcare [00:12:00] - European health data space and public engagement [00:14:00] - Opt-out provisions and public interest in European health data space [00:16:00] - Setting standards and policy compatibility in Europe [00:18:00] - Learning from historical approaches in healthcare data strategies [00:20:00] - Digital health literacy and public engagement [00:22:00] - Simplifying communication in digital health [00:24:00] - Role of patient leaders and public deliberation in health policy [00:26:00] - Public expectations on health data usage [00:28:00] - Economics of digital health and ROI [00:30:00] - Utilizing health data for policy and research [00:32:00] - Interoperability and investment in digital health infrastructure [00:34:00] - Shifting towards a prevention-based health system [00:36:00] - Workforce and capacity building in digital health [00:38:00] - Automation and the future of health workforce
Switzerland, AI and Liquid Biopsies
AI and predictive modeling to understand an individual’s immune system function and predict treatment response are still in very early stages. We dream about precision medicine and getting every answer we can for ourselves when we get sick. However, if we look at genomics, only about 20 percent of human coding genes are well-studied. The remaining 80 percent (about 16,000 genes, along with the proteins they make) are largely a mystery. In this episode, you will hear more about the field of immuno-oncology, understand the correlation between tumor development and immune system response, and trends in cancer detection and prevention, especially liquid biopsies - tests for detecting tumors in blood samples. Speaker: Brian Hashemi - Executive Chairman and CEO of Novigenix - a Swiss-based biotech company using AI and RNA sequence analysis to capture the cancer immunity cycle during the multi-stage disease progression and response to therapy. www.facesofdigitalhealth.com https://fodh.substack.com/ Show notes: [00:02:00] The use of AI and RNA sequence analysis in capturing the cancer immunity cycle and disease progression [00:04:00] Biotech in Switzerland [00:06:00] The impact of Swiss biotech capabilities on global healthcare and the specific advancements made by Swiss companies in the field. [00:08:00] Predictions and hopes for the future of healthcare technology, especially in the realms of cancer detection and treatment. [00:10:00] Challenges and opportunities in biotech, and the role of AI in advancing healthcare. [00:12:00] Challenges in Colorectal Cancer Screening [00:14:00] The Impact of Liquid Biopsy on Clinical Trials and Drug Development [00:16:00] Market Adoption and Patient Accessibility to Liquid Biopsy Tests [00:18:00] The Future of Liquid Biopsy and Precision Medicine [00:20:00] Real-world Application and Impact of Novel Biomarkers [00:22:00] Expanding the Reach of Novel Diagnostics Beyond Switzerland [00:24:00] Partnerships and Collaborations to Accelerate Adoption
Healthtech in the GCC Countries: Focus on Infrastructure and Export Capabilities
The Gulf Cooperation Council (GCC) brings together six Arab countries – Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates When one reads about the GCC countries, there’s nothing but the impression of prosperity: high investments, determination, and enthusiasm in tech-supported healthcare. The spending on healthcare by the GCC governments is on an astronomical rise. From a regionwide US$2.4 billion in 2016, it rose to more than US$30 billion in 2021 and is projected to surpass US$104 billion this year, according to a report from the UAE Ministry of Economy. In this episode, Pilar Fernandez HermidaInternational Go-to-Market expert with 20+ years of experience launching sales & partner ecosystem strategies, talks about the potential of the Middle East and MENA region for healthtech companies, the culture in the Middle East, how to interpret different style of communication here, what are the common entrepreneurial misconceptions, and where to find opportunities. Pilar says that the entrepreneurial spirit here is 10-times as strong as in the US, and that biotech and drug development are the next thing to watch for in the region. www.facesofdigitalhealth.com Newsletter: https://fodh.substack.com/ Show notes: [00:02:00] Pilar Fernandez Hermida, an expert in healthcare market strategies, shares insights from Abu Dhabi. [00:04:00] Analysis of the healthcare infrastructure development in GCC post-pandemic. [00:08:00] The role of expats in the Middle East's healthcare transformation. [00:10:00] Public-private partnerships as key opportunities. [00:12:00] Cultural considerations for startups in the GCC. [00:14:00] Misconceptions about the Middle Eastern healthcare market. [00:18:00] Building long-term relationships in business. [00:20:00] Navigating diverse cultural communication in healthcare. [00:24:00] Comparing the entrepreneurial spirit in the Middle East with the U.S. and Europe. [00:28:00] Strategic advice for healthcare entrepreneurs targeting the GCC. [00:30:00] Importance of understanding regulations and digital maturity in MENA. [00:32:00] Future potential in biotech and digital health in the GCC. [00:36:00] The convergence of digital health and biotech.
DTx in 2024: Where Are We With Business and Reimbursement Models? (Andy Molnar)
In the last few years, we've witnessed a whirlwind of developments in the world of Digital Therapeutics (DTx) - from FDA approvals sparking optimism for the industry, to the establishment of regulatory frameworks in countries like Germany, France, and Belgium. However, in 2023, the industry faced a stark reality check, marked by the fall of some key players and healthcare systems' hesitancy towards embracing and financing these innovations. This turbulence has reshaped strategies and raised critical questions about the future of DTx. 🔍 In this episode learn more about: 📊 The current state of the DTx industry in 2024, 🗣️ Key debates of digital therapies industry players, 🌐 Advocacy efforts pushing the boundaries for global adoption, 🚀 Strategies to accelerate the integration of digital therapies worldwide. Newsletter: fodh.substack.com Website: www.facesofdigitalhealth.com
What Factors Should You Take into Account when Designing ePROs - Electronic Patient Reported Outcomes Solutions?
Patient-reported outcomes (PROs) have become increasingly integral in healthcare for assessing the effectiveness of treatments from the patient's perspective. It sounds like a reasonable step in improving clinical research and care provision, but gathering data can be more difficult then you may think. It isn't easy to get to marginalized communities. There are language barriers in collecting data. There are cultural aspects that impact responses. So, how can you design useful electronic solutions for patient-reported outcomes? Hear from Mustafa Ali Syed, Researcher at the Manchester Academic Health Science Centre, The University of Manchester, and Ben James, Co-founder/Chief Design Officer at uMotif - ePRO, an engagement platform designed to power clinical and real-world research. Both are co-authors of a recently published paper titled Exploring the Cross-cultural Acceptability of Digital Tools for Pain Self-reporting. www.facesofdigitalhealth.com Newsletter: https://fodh.substack.com/ Show notes: 00:00:00 Why Do PROs Matter? 00:04:00 Evolution of Data Collection 00:06:00 Importance of Diversity in Clinical Trials 00:08:00 Ethnicity, Culture, and Pain Perception 00:12:00 The Role of Technology in PROs 00:14:00 Designing Inclusive Digital Solutions 00:20:00 Challenges in Engaging Targeted Populations 00:22:00 Language and Communication Barriers 00:26:00 The Future of PRO Research